Drug Cos. Put Off Planning For Generic Competition

Law360, New York (August 23, 2006, 12:00 AM EDT) -- Even with billions of dollars at stake, pharmaceutical companies are surprisingly slow to prepare for the competitive onslaught brought by generic drugs, a new study concludes.

The study found that a whopping 46% of the surveyed companies only started defending their licensed pharmaceuticals two to four years before patent expiration. 18% launched protection strategies even later, waiting past the two-year countdown to do anything.

The report indicated that in the current legal environment, in which some pharmaceutical companies file abbreviated new drug applications years before patent...
To view the full article, register now.

Law360 UK

UK Financial Services

Read Our Latest UK Legal News & Analysis

Financial Services Law360 UK and Insurance Law360 UK provide breaking news and in-depth analysis on U.K. and European Union regulation, enforcement, legislation, and litigation involving banks, investment firms, insurers, and more.